kt-2000 series / Rakovina Therap, University of British Columbia - LARVOL DELTA

Rakovina Therapeutics Inc. Receives Notice of Allowance for New U.S. Patent Covering kt-2000 series PARP Inhibitors (GlobeNewswire) - "Rakovina Therapeutics Inc...announced that the Company has received notice of allowance from the Untied States Patent and Trademark Office (USPTO) for a patent entitled 'Tricyclic Inhibitors of Poly(ADP-Ribose) Polymerase.'....The granted patent claims cover the composition of matter and uses of drug candidates from Rakovina Therapeutics’ kt-2000 series, one of three novel series of DNA-damage response (DDR) inhibitors being researched by the Company as potential targeted cancer therapies under a collaborative research agreement with the University of British Columbia."

Patent • Oncology